Liu et al. also reported that that cancer cells with overexpressed FKBP12 are more sensitive to doxorubicin revealing how the level of FKBP12 may serve as a predictor of the responsiveness to anticancer treatment targeting the MDM2-p53 pathway [20]. The gene discussed is FKBP1A; the disease is cancer.